Novel Cardiovascular Therapies
Emerging and recently approved cardiovascular therapies including RNA-based drugs, gene therapy, cardiac myosin activators, and anti-inflammatory agents.
## Overview
Cardiovascular pharmacology is undergoing a transformation driven by advances in RNA therapeutics, targeted protein degradation, gene therapy, and precision medicine. Several novel agents have reached clinical use or late-stage trials, addressing targets previously considered undruggable.
## RNA-Based Therapeutics
- **Inclisiran**: A small interfering RNA (siRNA) that silences hepatic PCSK9 mRNA production. Administered subcutaneously twice yearly after initial dosing. Reduces LDL by 50% on top of statins. Approved for hypercholesterolemia. Unlike monoclonal antibodies (evolocumab, alirocumab), inclisiran works intracellularly at the mRNA level, offering infrequent dosing.
- **Vutrisiran and patisiran**: siRNAs targeting transthyretin (TTR) mRNA for transthyretin amyloid cardiomyopathy (ATTR-CM). Vutrisiran (quarterly subcutaneous) showed mortality and hospitalization reduction in HELIOS-B. Represents a shift from stabilizing the misfolded protein (tafamidis) to eliminating its production.
- **Olpasiran and zerlasiran**: Target lipoprotein(a) [Lp(a)] via antisense or siRNA approaches. Lp(a) is a genetically determined cardiovascular risk factor with no approved pharmacotherapy. These agents reduce Lp(a) by 90-95%. Phase 3 outcome trials (OCEAN(a), ACCLAIM) are ongoing.
## Cardiac Myosin Modulators
- **Omecamtiv mecarbil**: A cardiac myosin activator that increases the number of myosin heads engaging with actin, enhancing systolic function without raising intracellular calcium. The GALACTIC-HF trial showed modest reduction in heart failure events. Unique mechanism avoids the arrhythmia and oxygen demand concerns of traditional inotropes.
- **Mavacamten and aficamten**: Cardiac myosin inhibitors for hypertrophic cardiomyopathy (HCM). They reduce the hypercontractile state by decreasing the proportion of myosin in the super-relaxed state. Mavacamten (approved) and aficamten (Phase 3) represent the first targeted therapies for obstructive HCM, reducing the need for septal myectomy.
## Anti-Inflammatory Approaches
The CANTOS trial proved that targeting inflammation (canakinumab, an IL-1 beta antibody) reduces cardiovascular events independently of lipid lowering. However, increased infection risk limited its adoption. Colchicine (LoDoCo2, COLCOT trials) at low dose (0.5 mg daily) reduced cardiovascular events post-MI and in stable CAD with a favorable safety profile. It is now the most accessible anti-inflammatory strategy for ASCVD.
## Gene Therapy
- **VERVE-101**: An in vivo base-editing therapy that permanently inactivates the PCSK9 gene in hepatocytes. A single IV infusion reduced LDL by approximately 55% in the heart-1 trial. Raises the possibility of a one-time treatment replacing lifelong drug therapy.
- **TTR gene silencing**: CRISPR-based approaches (e.g., nexiguran ziclumeran) offer single-dose knockout of TTR production for ATTR cardiomyopathy.
## SGLT2 Inhibitors: Expanding Indications
Originally developed for diabetes, empagliflozin and dapagliflozin are now approved for HFrEF, HFpEF, and CKD regardless of diabetes status. Mechanisms include osmotic diuresis, improved myocardial energetics (ketone utilization), anti-fibrotic effects, and reduction in epicardial fat. They represent the most important new drug class in cardiovascular medicine in the past decade.
## Key Takeaways
- RNA therapeutics (siRNA, ASO) enable infrequent dosing for chronic conditions
- Cardiac myosin modulators provide targeted therapy for HF and HCM
- Low-dose colchicine is the most practical anti-inflammatory CV therapy
- Gene editing may enable one-time treatments for lifelong cardiovascular risk factors